Arantxa Berzosa Sánchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arantxa Berzosa Sánchez has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Epalza
Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre Pediatric Research and Clinical Trials Unit (UPIC), Instituto de Investigación Sanitaria Hospital 12 de Octubre (IMAS12), Madrid, Spain
2 shared publications - José Tomás Ramos-Amador
Pediatric Infectious Diseases Unit. Department of Pediatrics, Hospital Universitario Doce de Octubre, Madrid, Spain
2 shared publications - María Luisa Navarro
Paediatric Infectious Diseases Unit Gregorio Marañon General Hospital Madrid Spain
2 shared publications - Talía Sainz
Pediatrics, Infectious Diseases and Tropical Medicine, University Hospital La Paz, 28046 Madrid, Spain
2 shared publications Anna Gamell
Servicio de Enfermedades Infecciosas, Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain
1 shared publicationCristina Epalza Ibarrondo
Unidad de Enfermedades Infecciosas Pediátricas, Servicio de Pediatría, Hospital Universitario 12 de Octubre, Instituto deInvestigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 104 (5) , 504172
New advances and challenges in sexually transmitted infections in the adolescent population. Document of the Working Group on HIV and STIs of the Spanish Society of Pediatric Infectious Diseases (SEIP)
- 15 May 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 104 (5) , 504172
Open AccessNew advances and challenges in sexually transmitted infections in the adolescent population. Document of the Working Group on HIV and STIs of the Spanish Society of Pediatric Infectious Diseases (SEIP)
- Open Access
- 23 December 2023
- Published by MDPI AG in Microorganisms
- Vol. 12 (1) , 30
Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
Background: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose schedule and to describe possible HIV-related factors that may affect the immunogenic response. Methods: A multicenter prospective study was designed, including CALHIV followed in five hospitals in Madrid, between 2019 and 2021. Two doses of the Men ACWY-TT vaccine were administered. Serum bactericidal antibody (SBA) assays using rabbit complement (rSBA) against serogroups C, W, and Y were used to determine seroprotection and vaccine response (the proportion achieving a putative protective titer of ≥eight or a ≥four-fold rise in titer from baseline). Serum was collected at baseline, and at 3 and 12 months after vaccination. Results: There were 29 CALHIV included, 76% of whom were perinatally infected. All were receiving TAR and presented a good immunovirological and clinical status overall. At baseline, 45% of CALHIV had seroprotective titers to at least one serogroup, with individual seroprotection rates of 24%, 28%, and 32% against C, W, and Y, respectively. After a two-dose schedule, vaccine response was 83% for each serogroup, eliciting a vaccine response to all serogroups in 69% of them. One year after vaccination, 75% of CALHIV maintained seroprotective titers against the C serogroup, and 96% against W and Y. None of the HIV-related characteristics analyzed could predict vaccine response or antibody duration. Conclusions: CALHIV who received effective TAR and presented a good immuno-virological situation achieved an appropriate vaccine response after two doses of the Men ACWY-TT vaccine, and antibody-mediated protection against serogroups C, W, and Y was maintained in more than 70% of the patients one year after vaccination.
- 23 December 2023
- Published by MDPI AG in Microorganisms
- Vol. 12 (1) , 30
Open AccessImmunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV
Background: Children and adolescents living with HIV (CALHIV) are at high risk of meningococcal infections and may present lower immune responses to vaccines. The objectives of this study were to assess the immunogenicity of the quadrivalent Men ACWY-TT vaccine (Nimenrix®) in CALHIV after a two-dose schedule and to describe possible HIV-related factors that may affect the immunogenic response. Methods: A multicenter prospective study was designed, including CALHIV followed in five hospitals in Madrid, between 2019 and 2021. Two doses of the Men ACWY-TT vaccine were administered. Serum bactericidal antibody (SBA) assays using rabbit complement (rSBA) against serogroups C, W, and Y were used to determine seroprotection and vaccine response (the proportion achieving a putative protective titer of ≥eight or a ≥four-fold rise in titer from baseline). Serum was collected at baseline, and at 3 and 12 months after vaccination. Results: There were 29 CALHIV included, 76% of whom were perinatally infected. All were receiving TAR and presented a good immunovirological and clinical status overall. At baseline, 45% of CALHIV had seroprotective titers to at least one serogroup, with individual seroprotection rates of 24%, 28%, and 32% against C, W, and Y, respectively. After a two-dose schedule, vaccine response was 83% for each serogroup, eliciting a vaccine response to all serogroups in 69% of them. One year after vaccination, 75% of CALHIV maintained seroprotective titers against the C serogroup, and 96% against W and Y. None of the HIV-related characteristics analyzed could predict vaccine response or antibody duration. Conclusions: CALHIV who received effective TAR and presented a good immuno-virological situation achieved an appropriate vaccine response after two doses of the Men ACWY-TT vaccine, and antibody-mediated protection against serogroups C, W, and Y was maintained in more than 70% of the patients one year after vaccination.
- 6 July 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (10) , 824-826
SARS-CoV-2 Infection in Children and Adolescents Living With HIV in Madrid
Multicenter study designed to describe epidemiologic and clinical characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive cases registered among children and adolescents living with HIV (CALWH). SARS-CoV-2 infection was confirmed in 13.3% of CALWH, with all patients presenting mild symptoms, and the outcome was good in all patients. None of the HIV- and antiretroviral treatment-related variables studied were associated with greater infection risk or could be considered protective.
- 6 July 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (10) , 824-826
SARS-CoV-2 Infection in Children and Adolescents Living With HIV in Madrid
Multicenter study designed to describe epidemiologic and clinical characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive cases registered among children and adolescents living with HIV (CALWH). SARS-CoV-2 infection was confirmed in 13.3% of CALWH, with all patients presenting mild symptoms, and the outcome was good in all patients. None of the HIV- and antiretroviral treatment-related variables studied were associated with greater infection risk or could be considered protective.